Commentary

Video

Dr Mayer on Niraparib Plus Dostarlimab in ER+ BRCA/PALB2-Mutated Breast Cancer

Author(s):

Erica L. Mayer, MD, MPH

Fact checked by:

Ashling Wahner ,Chris Ryan
Conference|San Antonio Breast Cancer Symposium

Erica L. Mayer, MD, MPH, discusses findings with neoadjuvant niraparib plus dostarlimab in ER-positive, HER2-negative, BRCA/PALB2-mutated breast cancer.

Erica L. Mayer, MD, MPH, director, clinical research, Dana-Farber Cancer Institute; associate professor, medicine, Harvard Medical School, discusses findings with the use of neoadjuvant niraparib (Zejula) plus dostarlimab-gxly (Jemperli) from the estrogen receptor (ER)–positive, HER2-negative, BRCA/PALB2-mutated breast cancer cohort of the phase 2 TBCRC 056 trial (NCT04584255).

Related Videos
2 experts are featured in this series.
2 experts are featured in this series.
Gustavo Werutsky, MD, PhD, medical oncologist, Breast Cancer Program, Hospital Moinhos de Vento; investigator, Oncology Research Centre, Hospital São Lucas PUCRS University
Ewa Kalinka, MD, PhD
Rohan Garje, MD
Aparna Parikh, MD, medical oncologist, Massachusetts General Hospital
Tycel J. Phillips, MD, MPH
Dr Baljevic on Selinexor Plus Pomalidomide/Dexamethasone in R/R Myeloma
Dr Al Malki on the Potential Use of TSC-100 and TSC-101 After Transplant in AML, ALL, and MDS
Naval G. Daver, MD,
Related Content
Sotorasib doublet gets approved for KRAS G12C–mutated CRC, acalabrutinib triplet is cleared for previously untreated MCL, and more from OncLive.
January 18th 2025

The OncFive: Top Oncology Articles for the Week of 1/12

MedNews Week
January 1st 2025

DESTINY-Breast06 Data Demonstrate the Role of T-DXd in HER2-Low and -Ultralow Breast Cancer: With Chandler Park, MD; and Guiseppe Curigliano, MD, PhD

FDA
January 17th 2025

FDA Approves Datopotamab Deruxtecan for Unresectable or Metastatic HR+/HER2-Negative Breast Cancer

OncLive On Air
September 11th 2024

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

Bradley McGregor, MD
January 15th 2025

Nivolumab Plus Ipilimumab May Offer Efficacious Therapeutic Approach in Rare GU Cancers

Erica L. Mayer, MD, MPH
January 13th 2025

Neoadjuvant Niraparib Plus Dostarlimab Data Support Development of Non-Chemo Approaches in BRCA+, ER+ Breast Cancer